ClinicalTrials.gg
RecruitingNCT05222594Updated May 7, 2026

Computational Neuroscience of Language Processing in the Human Brain

An interventional study of Behavioral tasks during intracranial monitoring in Language and Epilepsy, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Apr 2021, registered Jan 2022).
  • Started Apr 2021; still recruiting 5 years 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Language is a signature human cognitive skill, but the precise computations that support language understanding remain unknown. This study aims to combine high-quality human neural data obtained through intracranial recordings with advances in computational modeling of human cognition to shed light on the construction and understanding of speech.

Read the detailed description

The neural architecture of language is the foundation for the highest form of human interaction. Prior work has identified a network of frontal and temporal brain areas that selectively support language processing, but the precise computations that underlie our ability to extract meaning from sequences of words have remained unknown. The standard approaches in human cognitive neuroscience lack the spatial and temporal resolution necessary for precise comparisons to computational models. To bridge this gap in knowledge, neural responses to language stimuli will be collected from epileptic patients undergoing intracranial monitoring. Overall, these data will be used to identify cortical maps of different linguistic manipulations and to better understand properties of the human language network.

02

Conditions studied

  • Language
  • Epilepsy

Keywords

  • language
  • computational neuroscience
  • epilepsy
03

In context

Language

243 studies on the registry are indexed under Language; 76 are open to participants now.

This study's planned enrollment of 40 is below the median of 65 across 158 interventional studies indexed under Language.

Browse Language studies →

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,586 studies on the registry; 447 are open to participants now.

Of its 222 completed or terminated interventional studies of FDA-regulated products, 168 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • clinical indications to proceed with intracranial monitoring involving the left cerebral hemisphere, as determined by a multidisciplinary epilepsy surgery team
  • the ability to comply with test directions and provide
  • between ages 18 - 85

Exclusion criteria

Exclusion Criteria:

  • inability to understand or perform the task outlined in the protocol, or who are unwilling or unable to participate
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Other
    Epileptic participants undergoing intracranial monitoring

    Patients with pharmaco-resistant epilepsy undergoing intracranial monitoring involving the left cerebral hemisphere.

    Other: Behavioral tasks during intracranial monitoring

Interventions

  • OtherBehavioral tasks during intracranial monitoring

    Participants will listen to sentences and stories while neural data are recorded through electrodes placed for clinical purposes.

06

What researchers measure

Primary outcomes

  1. Cortical maps of linguistic responses

    By using sEEG intracranial recordings of the brain, EEG power in frequency bands will reflect cortical maps of responses to different linguistic manipulations, informing the functional organization of the human language system. Power is measured in arbitrary units; higher power reflects greater activity at the investigated frequency.

    Time frame: Throughout intracranial monitoring period, up to approximately 10 days

  2. Neural time-courses during naturalistic language comprehension

    Time-courses of neural response to language across diverse parts of the language network. These data will be used to predict across-time variation in response strength from the properties of linguistic input.

    Time frame: Throughout intracranial monitoring period, up to approximately 10 days

  3. Brain scores for diverse artificial neural network (ANN) language models

    Human neural data will be compared to ANN language models to test how well these models predict human responses to language and why. There are no minimum or maximum scores. Higher values mean better model predictivity (i.e., a better match between model representations and neural responses).

    Time frame: Throughout intracranial monitoring period, up to approximately 10 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Blank I, Balewski Z, Mahowald K, Fedorenko E. Syntactic processing is distributed across the language system. Neuroimage. 2016 Feb 15;127:307-323. doi: 10.1016/j.neuroimage.2015.11.069. Epub 2015 Dec 5. PubMed 26666896 ↗
  • Blank IA, Fedorenko E. No evidence for differences among language regions in their temporal receptive windows. Neuroimage. 2020 Oct 1;219:116925. doi: 10.1016/j.neuroimage.2020.116925. Epub 2020 May 11. PubMed 32407994 ↗
  • Fedorenko E, Behr MK, Kanwisher N. Functional specificity for high-level linguistic processing in the human brain. Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16428-33. doi: 10.1073/pnas.1112937108. Epub 2011 Sep 1. PubMed 21885736 ↗
  • Fedorenko E, Blank IA. Broca's Area Is Not a Natural Kind. Trends Cogn Sci. 2020 Apr;24(4):270-284. doi: 10.1016/j.tics.2020.01.001. Epub 2020 Feb 20. PubMed 32160565 ↗
  • Fedorenko E, Duncan J, Kanwisher N. Language-selective and domain-general regions lie side by side within Broca's area. Curr Biol. 2012 Nov 6;22(21):2059-62. doi: 10.1016/j.cub.2012.09.011. Epub 2012 Oct 11. PubMed 23063434 ↗
  • Fedorenko E, Hsieh PJ, Nieto-Castanon A, Whitfield-Gabrieli S, Kanwisher N. New method for fMRI investigations of language: defining ROIs functionally in individual subjects. J Neurophysiol. 2010 Aug;104(2):1177-94. doi: 10.1152/jn.00032.2010. Epub 2010 Apr 21. PubMed 20410363 ↗
  • Fedorenko E, Nieto-Castanon A, Kanwisher N. Lexical and syntactic representations in the brain: an fMRI investigation with multi-voxel pattern analyses. Neuropsychologia. 2012 Mar;50(4):499-513. doi: 10.1016/j.neuropsychologia.2011.09.014. Epub 2011 Sep 17. PubMed 21945850 ↗
  • Fedorenko E, Scott TL, Brunner P, Coon WG, Pritchett B, Schalk G, Kanwisher N. Neural correlate of the construction of sentence meaning. Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):E6256-E6262. doi: 10.1073/pnas.1612132113. Epub 2016 Sep 26. PubMed 27671642 ↗
  • Mollica F, Siegelman M, Diachek E, Piantadosi ST, Mineroff Z, Futrell R, Kean H, Qian P, Fedorenko E. Composition is the Core Driver of the Language-selective Network. Neurobiol Lang (Camb). 2020 Mar 1;1(1):104-134. doi: 10.1162/nol_a_00005. eCollection 2020. PubMed 36794007 ↗
  • Nieto-Castanon A, Fedorenko E. Subject-specific functional localizers increase sensitivity and functional resolution of multi-subject analyses. Neuroimage. 2012 Nov 15;63(3):1646-69. doi: 10.1016/j.neuroimage.2012.06.065. Epub 2012 Jul 8. PubMed 22784644 ↗
  • Norman-Haignere S, Kanwisher NG, McDermott JH. Distinct Cortical Pathways for Music and Speech Revealed by Hypothesis-Free Voxel Decomposition. Neuron. 2015 Dec 16;88(6):1281-1296. doi: 10.1016/j.neuron.2015.11.035. PubMed 26687225 ↗
  • Pereira F, Lou B, Pritchett B, Ritter S, Gershman SJ, Kanwisher N, Botvinick M, Fedorenko E. Toward a universal decoder of linguistic meaning from brain activation. Nat Commun. 2018 Mar 6;9(1):963. doi: 10.1038/s41467-018-03068-4. PubMed 29511192 ↗
  • Shain C, Blank IA, van Schijndel M, Schuler W, Fedorenko E. fMRI reveals language-specific predictive coding during naturalistic sentence comprehension. Neuropsychologia. 2020 Feb 17;138:107307. doi: 10.1016/j.neuropsychologia.2019.107307. Epub 2019 Dec 24. PubMed 31874149 ↗
  • Siegelman M, Blank IA, Mineroff Z, Fedorenko E. An Attempt to Conceptually Replicate the Dissociation between Syntax and Semantics during Sentence Comprehension. Neuroscience. 2019 Aug 10;413:219-229. doi: 10.1016/j.neuroscience.2019.06.003. Epub 2019 Jun 11. PubMed 31200104 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05222594
Collaborators
Massachusetts Institute of Technology
Responsible party
Robert Mark Richardson (Director, Functional Neurosurgery, Massachusetts General Hospital) — Principal investigator
First posted
Feb 3, 2022
Start date
Apr 2, 2021
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
May 7, 2026

Study contacts

Evelina Fedorenko, PhD
Contact
evelina9@mit.edu
617-258-0670

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion